Anticonvulsant and behavioral profile of L-701,324, a potent, orally active antagonist at the glycine modulatory site on the N-methyl-D-aspartate receptor complex

Journal of Pharmacology and Experimental Therapeutics

Volumn 279, Issue 2, 1996, Pages 492-501

  Bristow, Linda J ^a,b   Hutson, Peter H ^a   Kulagowski, Janusz J ^a   Leeson, Paul D ^a   Matheson, Steven ^a   Murray, Fraser ^a   Rathbone, Denise ^a   Saywell, Kay L ^a   Thorn, Lynn ^a   Watt, Alan P ^a   Tricklebank, Mark D ^a  

^a NEUROSCIENCE RESEARCH CENTRE   (United Kingdom)

^b Merck Sharp & Dohme Limited   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

7 CHLORO 4 HYDROXY 3 (3 PHENOXYPHENYL) 2 QUINOLONE; ANTICONVULSIVE AGENT; DIZOCILPINE; GLYCINE RECEPTOR ANTAGONIST; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PENTETRAZOLE; PHENCYCLIDINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; AUDIOGENIC SEIZURE; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; DRUG POTENCY; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; MESOLIMBIC DOPAMINERGIC SYSTEM; MOUSE; NONHUMAN; NUCLEUS ACCUMBENS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT;

ADMINISTRATION, ORAL; ANIMALS; ANTICONVULSANTS; BRAIN; DIZOCILPINE MALEATE; DOPAMINE; EXCITATORY AMINO ACID ANTAGONISTS; MALE; MICE; MICE, INBRED DBA; MOTOR ACTIVITY; QUINOLONES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, GLYCINE; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 12644251062     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. AL-KHATIB, I., KARADAG, H. C. AND ULUGOL, A.: The behavioural effects of MK-801 injected into nucleus accumbens and caudate-putamen of rats. Pharmacol. Biochem. Behav. 52: 723-730, 1995.
2. ANIS, N. A., BERRY, S. C., BURTON, N. R. AND LODGE, D.: The dissociative anaesthetics, ketamine and PCP, selectively reduce excitation of central mammalian neurones by N-methyl-aspartate. Br. J. Pharmacol. 79: 565-575, 1983.
3. BALSTER, R. L., GRECH, D. M., MANSBACH, R. S., LI, H. AND WEBER, E.: Behavioural studies of the novel glycine-site NMDA antagonists ACEA-1011 and ACEA-1021 in rats. Soc. Neurosci. Abstr. 19: Abstract 197.16, p. 472, 1993.
4. BOWERS, M. B. AND HOFFMAN, F. J.: Homovanillic acid in rat caudate and prefrontal cortex following phencyclidine and amphetamine. Psychopharmacology 84: 136-137, 1984.
5. BRISTOW, L. J., FLATMAN, K. L., HUTSON, P. H., KULAGOWSKI, J. J., LEESON, P. D., YOUNG, L. AND TRICKLEBANK, M. D.: The atypical neuroleptic profile of the glycine/N-methyl-D-aspartate receptor antagonist, L-701,324, in rodents. J. Pharmacol. Exp. Ther. 277: 578-586, 1996.
6. BRISTOW, L. J., FLATMAN, K. L., YOUNG, L., HUTSON, P. H. AND TRICKLEBANK, M. D.: The glycine/NMDA receptor antagonist, L-701,324, blocks the neurochemical and behavioural effects of amphetamine in rodents. Br. J. Pharmacol. 114: 321P, 1995.
7. BRISTOW, L. J., HUTSON, P. H., THORN, L. AND TRICKLEBANK, M. D.: The glycine/ NMDA receptor antagonist, R-(+)-HA-966, blocks activation of the mesolimbic dopaminergic system induced by phencyclidine and dizocilpine (MK-801) in rodents. Br. J. Pharmacol. 108: 1156-1163, 1993.
8. CARTER, C., RIVY, J. P. AND SCATTON, B.: Ifenprodil and SL 82.0715 are antagonists at the polyamine site of the N-methyl-d-aspartate (NMDA) receptor. Eur. J. Pharmacol. 164: 611-612, 1989.
9. DANYSZ, W., PARSONS, C. G., BRESINK, I. AND QUACK, G.: Glutamate in CNS disorders. Drugs News Perspect. 8: 261-277, 1995.
10. 3H]d-AP5 binding sites on brain membranes and anticonvulsant activity. Brain Res. 382: 169-173, 1986.
11. DEUTCH, A. Y., TAM, S. Y., FREEMAN, A. S., BOWERS, M. B. AND ROTH, R. H.: Mesolimbic and mesocortical dopamine activation induced by phencyclidine: Contrasting pattern to striatal response. Eur. J. Pharmacol. 134: 257-264, 1987.
12. GILL, R., HARGREAVES, R. J. AND KEMP, J. A.: Neuroprotective effects of the glycine site antagonist (+)-cis-4-methyl-HA-966 (L-687,414) in a rat focal ischaemia model. J. Cereb. Blood Flow Metab. 11: suppl. 2, S304, 1991.
13. GRIMWOOD, S., KULAGOWSKI, J. J., MAWER, I. M., ROWLEY, M., LEESON, P. D. AND FOSTER, A. C.: Allosteric modulation of the glutamate site on the NMDA receptor by four novel glycine site antagonists. Eur. J. Pharmacol. 290: 221-226, 1995.
14. HARGREAVES, R. J., RIGBY, M., SMITH, D. AND HILL, R. G.: Lack of effect of L-687,414 ((+)-cis-4-methyl-HA-966), an NMDA receptor antagonist acting at the glycine site, on cerebral glucose metabolism and cortical neuronal morphology. Br. J. Pharmacol. 110: 36-42, 1993a.
15. HARGREAVES, R. J., RIGBY, M., SMITH, D., HILL, R. G. AND IVERSEN, L. L.: Competitive as well as uncompetitive N-methyl-d-aspartate receptor antagonists affect cortical neuronal morphology and cerebral glucose metabolism. Neurochem. Res. 18: 1263-1269, 1993b.
16. HIRAMATSU, M., CHO, A. K. AND NABESHIMA, T.: Comparison of the behavioural and biochemical effects of the NMDA receptor antagonists, MK-801 and phencyclidine. Eur. J. Pharmacol. 166: 359-366, 1989.
17. HUTSON, P. H., BRISTOW, L. J., THORN, L. AND TRICKLEBANK, M. D.: R-(+)-HA-966, a glycine/NMDA receptor antagonist, selectively blocks the activation of the mesolimbic dopamine system by amphetamine. Br. J. Pharmacol. 103: 2037-2044, 1991.
18. HYLDEN, J. L. K. AND WILCOX, G. L.: Intrathecal morphine in mice: A new technique. Eur. J. Pharmacol. 67: 313-316, 1980.
19. JAVITT, D. C. AND ZUKIN, S. R.: Recent advances in the phencyclidine model of schizophrenia. Am J. Psychiatry 148: 1301-1308, 1991.
20. JOHNSON, J. W. AND ASCHER, P.: Glycine potentiates the NMDA response in cultured mouse brain neurones. Nature (Lond.) 325: 529-531, 1987.
21. KEHNE, J. H., BARON, B. M., HARRISON, B. L., MCCLOSKEY, T. C., PALFREYMAN, M. G., POIROT, M., SALITURO, F. G., SIEGEL, B. W., SLONE, A. L., VAN GIERSBERGEN, P. L. M. AND WHITE, H. S.: MDL 100,458 and MDL 102,228: Two potent and selective glycine receptor antagonists with different functional profiles. Eur. J. Pharmacol. 284: 109-118, 1995.
22. KELLEY, A. E. AND DELFS, J. M.: Excitatory amino acid receptors mediate the orofacial stereotypy elicited by dopaminergic stimulation of the ventral striatum. Neuroscience 60: 85-95, 1994.
23. KELLEY, A. E. AND THRONE, L. C.: NMDA receptors mediate the behavioural effects of amphetamine infused into the nucleus accumbens. Brain Res. Bull. 29: 247-254, 1992.
24. KEMP, J. A., FOSTER, A. C., LEESON, P. D., PRIESTLEY, T., TRIDGETT, R., IVERSEN, L. L. AND WOODRUFF, G. N.: 7-Chlorokynurenic acid is a selective antagonist at the glycine modulatory site of the N-methyl-d-aspartate receptor complex. Proc. Natl. Acad. Sci. U.S.A. 85: 6547-6550, 1988.
25. KEMP, J. A. AND LEESON, P. D.: The glycine site of the NMDA receptor: 5 years on. Trends Pharmacol. Sci. 14: 20-25, 1993.
26. KEMP, J. A., PRIESTLEY, T., MARSHALL, G. R., LEESON, P. D. AND WILLIAMS, B. J.: Functional assessment of the actions of 4-methyl derivatives of HA-966 at the glycine site of the N-methyl-d-aspartate receptor. Br. J. Pharmacol. 102: 65P, 1991.
27. KOEK, W. AND COLPART, F. C.: Selective blockade of N-methyl-d-aspartate (NMDA)-induced convulsions by NMDA antagonists and putative glycine antagonists: Relationship with phencyclidine-like behavioral effects. J. Pharmacol. Exp. Ther. 252: 349-357, 1990.
28. KRETSCHMER, B. D., BUSBER, M. AND SCHMIDT, W. J.: Behavioural and neurochemical actions of the strychnine-insensitive glycine receptor antagonist, 7-chlorokynurenate, in rats. Eur. J. Pharmacol. 280: 37-45, 1995.
29. KULAGOWSKI, J. J., BAKER, R., CURTIS, N. R., LEESON, P. D., MAWER, I. M., MOSELEY, A. M., RIDGILL, M. P., ROWLEY, M., STANSFIELD, I., FOSTER, A. C., GRIMWOOD, S., HILL, R. G., KEMP, J. A., MARSHALL, G. R., SAYWELL, K. L. AND TRICKLEBANK, M. D.: 3′-(Arylmethyl)- and 3′-(aryloxy)-3-phenyl-4-hydroxyquinolin-2(H)-ones: Orally active antagonists of the glycine site on the NMDA receptor. J. Med. Chem. 37: 1402-1405, 1994.
30. KULAGOWSKI, J. J. AND LEESON, P. D.: Glycine-site NMDA receptor antagonists. Exp. Opin. Ther. Patents 5: 1061-1075, 1995.
31. KURUMAJI, A. AND MCCULLOCH, J.: Effects of MK-801 upon local cerebral glucose utilisation in conscious rats and in rats anaesthetised with halothane. J. Cereb. Blood Flow Metab. 9: 786-794, 1989.
32. LEESON, P. D., WILLIAMS, B. J., ROWLEY, M., MOORE, K. W., BAKER, R., KEMP, J. A., PRIESTLEY, T., FOSTER, A. C. AND DONALD, A. E.: Derivatives of 1-hydroxy-3-aminopyrrolidin-2-one (HA-966): Partial agonists at the glycine site of the NMDA receptor. Biorg. Med. Chem. Lett. 3: 71-76, 1993.
33. LODGE, D. AND JOHNSON, K. M.: Noncompetitive excitatory amino acid receptor antagonists. Trends Pharmacol. Sci. 11: 81-86, 1990.
34. MONYER, H., SPRENGEL, R., SCHOEPFER, R., HERB, A., HIGUCHI, M., LOMELI, H., BURNASHEV, N., SAKMANN, B. AND SEEBURG, P. H.: Heteromeric NMDA receptors: Molecular and functional distinction of subtypes. Science (Wash. DC) 256: 1217-1221, 1992.
35. MORIYOSHI, K., MASU, M., ISHII, T., SHIGEMOTO, R., MIZUNO, N. AND NAKANISHI, S.: Molecular cloning and characterization of the rat NMDA receptor. Nature (Lond.) 354: 31-37, 1991.
36. NAGATA, R., TANNO, N., KODO, T., AE, N., YAMAGUCHI, H., TANAKA, H., NAKAMURA, M., OGITA, K. AND YONEDA, Y.: Tricyclic quinoxalinediones: Highly in vivo active antagonists for the glycine binding site of the NMDA receptor. In Abstracts of the International Society for Neurochemistry Satellite Symposium on Excitatory Amino Acid Signalling, p. 83. Kyoto, Japan, 1995.
37. OLNEY, J. W., LABRUYERE, J. AND PRICE, M. T.: Pathological changes induced in cerebrocortical neurones by phencyclidine and related drugs. Science (Wash. DC) 244: 1360-1362, 1989.
38. O'NEILL, K. A. AND LIEBMAN, J. M.: Unique behavioural effects of the NMDA antagonist, CPP, upon injection into the medial pre-frontal cortex of rats. Brain Res. 435: 371-376, 1987.
39. PRIESTLEY, T., DANKS, P., MARSHALL, G. R., KEMP, J. A., KULAGOWSKI, J. J., LEESON, P. D. AND HILL, R. G.: L-701,324: A high affinity antagonist at the glycine-recognition site of the NMDA receptor. Br. J. Pharmacol. 113: 31P, 1994.
40. PULVIRENTI, L., SWERDLOW, N. R. AND KOOB, G. F.: Nucleus accumbens NMDA antagonist decreases locomotor activity produced by cocaine, heroin or accumbens dopamine but not caffeine. Pharmacol. Biochem. Behav. 40: 841-845, 1991.
41. RAO, T. S., KIM, H. S., LEHMANN, J., MARTIN, L. L. AND WOOD, P. L.: Selective activation of dopaminergic pathways in the mesocortex by compounds that act at the phencyclidine (PCP) binding site: Tentative evidence for PCP recognition sites not coupled to N-methyl-d-aspartate (NMDA) receptors. Neuropharmacology 29: 225-230, 1990.
42. ROWLEY, M., LEESON, P. D., STEVENSON, G. I., MOSELEY, A. M., STANSFIELD, I., SANDERSON, I., ROBINSON, L., BAKER, R., KEMP, J. A., MARSHALL, G. R., FOSTER, A. C., GRIMWOOD, S., TRICKLEBANK, M. D. AND SAYWELL, K. L.: 3-Acyl-4-hydroxyquinolin-2(1H)-ones: Systemically active anticonvulsants acting by antagonism at the glycine site of the N-methyl-d-aspartate receptor complex. J. Med. Chem. 36: 3386-3396, 1993.
43. SINGH, L., DONALD, A. E., FOSTER, A. C., HUTSON, P. H., IVERSEN, L. L., IVERSEN, S. D., KEMP, J. A., LEESON, P. D., MARSHALL, G. R., OLES, R. J., PRIESTLEY, T., THORN, L., THICKLEBANK, M. D., VASS, C. A. AND WILLIAMS, B. J.: Enantiomers of HA-966 (3-amino-1-hydroxypyrrolid-2-one) exhibit distinct central nervous system effects: (+)-HA-966 is a selective glycine/N-methyl-d-aspartate receptor antagonist, but (-)-HA-966 is a potent γ-butyrolactone-like sedative. Proc. Natl. Acad. Sci. U.S.A. 87: 347-351, 1990.
44. SVENSSON, A. AND CARLSSON, M. L.: Injection of the competitive NMDA receptor antagonist AP-5 into the nucleus accumbens of monoamine-depleted mice induces pronounced locomotor stimulation. Neuropharmacology 31: 513-518, 1992.
45. TANAKA, H., KATO, T., MARUOKA, Y., YASUDA, H., KAWABE, A., KAWASHIMA, C., OHTANI, K. AND NAKAMURA, M.: Pharmacological profile of SM-18400, a novel strychnine-insensitive glycine site antagonist. In Abstracts of the International Society for Neurochemistry Satellite Symposium on Excitatory Amino Acid Signalling, p. 82. Kyoto, Japan, 1995.
46. TRICKLEBANK, M. D., BRISTOW, L. J., HUTSON, P. H., LEESON, P. D., ROWLEY, M., SAYWELL, K., SINGH, L., TATTERSALL, F. D., THORN, L. AND WILLIAMS, B. J.: The anticonvulsant and behavioural profile of L-687,414, a partial agonist acting at the glycine modulatory site on the N-methyl-d-aspartate (NMDA) receptor complex. Br. J. Pharmacol. 113: 729-736, 1994.
47. TRICKLEBANK, M. D., SINGH, L., OLES, R., PRESTON, C. AND IVERSEN, S. D.: The behavioural effects of MK-801: A comparison with antagonists acting noncompetitively and competitively at the NMDA receptor. Eur. J. Pharmacol. 167: 127-135, 1989.
48. WARNER, D. S., MARTIN, H., LUDWIG, P., MCALLISTER, A., KEANA, J. F. W. AND WEBER, E.: In vivo models of cerebral ischemia: Effects of parentally administered NMDA receptor glycine site antagonists. J. Cereb. Blood Flow Metab. 15: 188-196, 1995.
49. WILLETTS, J., BALSTER, R. L. AND LEANDER, J. D.: The behavioural pharmacology of NMDA receptor antagonists. Trends Pharmacol. Res. 11: 423-428, 1991.
50. WONG, E. H. F., KEMP, J. A., PRIESTLEY, T., KNIGHT, A. R., WOODRUFF, G. N. AND IVERSEN, L. L.: The anticonvulsant MK-801 is a potent N-methyl-d-aspartate antagonist. Proc. Natl. Acad. Sci. U.S.A. 83: 7104-7108, 1986.
51. WOODWARD, R. M., HUETTNER, J. E., GUASTELLA, J., KEANA, J. F. W. AND WEBER, E.: In vitro pharmacology of ACEA-1021 and ACEA-1031: Systemically active quinoxalinediones with high affinity and selectivity for N-methyl-d-aspartate receptor glycine sites. Mol. Pharmacol. 47: 568-581, 1995.